This information was published, 2016-06-28 10:38 CEST (GLOBE NEWSWIRE) —
The presentation “A personalised metal implant for resurfacing of local cartilage damage in the knee joint – early results on 10 patients” by N. Martinez-Carranza, D. Roberts, M. Högström och A. Stålman will be held by Dr. Nicolas Martinez-Carranza, Karolinska Institute, Stockholm.
The results show statistically significant clinical improvements from preoperatively to 12 and 24 months’ follow-up of the patients. No complications have been noted and X-rays at follow-up show that the implants are in a correct and secure position.
”This is the first time 2-years data will be presented. The positive 1-year follow-up results previously presented are here followed by equally good 2-years’ results, which of course is pleasing and in line with our expectations.” comments Leif Ryd, Senior medical advisor and board member, Episurf Medical.
”We now have accumulated clinical evidence that demonstrates good implant safety and patient well-being. 2 years’ follow-up is generally considered an accepted threshold for clinical success. We can therefore expect increased acceptance from the orthopedic profession.” says Rosemary Cunningham Thomas, CEO, Episurf Medical.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.